Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Shanghai - Delayed Quote CNY

Shanghai Junshi Biosciences Co., Ltd. (688180.SS)

Compare
30.96
-0.99
(-3.10%)
As of 11:29:57 AM GMT+8. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 688180.SS

Recent News: 688180.SS

View More
Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe

Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe
GlobeNewswire last month
Junshi Biosciences Announces Toripalimab’s Approval in Australia

Junshi Biosciences Announces Toripalimab’s Approval in Australia
GlobeNewswire last month
Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab

Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab
GlobeNewswire 3 months ago
Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR

Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR
GlobeNewswire 4 months ago
Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab

Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab
GlobeNewswire 5 months ago
Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates

Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
GlobeNewswire 5 months ago
Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma

Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma
GlobeNewswire 6 months ago
Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab

Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
GlobeNewswire 6 months ago
Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
GlobeNewswire 7 months ago
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC
GlobeNewswire 7 months ago
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
GlobeNewswire 8 months ago
View More

Related Tickers

2171.HK CARsgen Therapeutics Holdings Limited
16.520
-1.43%
 
2696.HK Shanghai Henlius Biotech, Inc.
27.300
-3.36%
 
9939.HK Kintor Pharmaceutical Limited
1.120
-6.67%
 
AVBP ArriVent BioPharma, Inc.
23.70
-2.79%
 
1548.HK GENSCRIPT BIO
12.660
-4.52%
 
ITOS iTeos Therapeutics, Inc.
7.00
-0.99%
 
6160.HK BeiGene, Ltd.
167.500
+3.65%
 
1801.HK INNOVENT BIO
41.300
-4.40%
 
ONC BeiGene, Ltd.
278.38
+7.48%
 
LEGN Legend Biotech Corporation
36.72
+0.52%